DATE: April 25, 2017
TIME: 10:00am PT, 1:00pm ET
Immunotherapy has emerged as one of the most promising options for the future treatment of a growing number of cancers and is touted to be the next revolution in our fight against this complex disease. One of the most effective modalities of treatment, thus far, has been in the form of immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors.
Current biomarkers and immunohistochemistry (IHC) assays are not accurate predictors of which individuals are most likely to respond or benefit from immunotherapeutic agents, thus prompting the need to identify better biomarkers that can guide therapy selection in the future.
Next-generation sequencing (NGS) offers clinical researchers a cost-efficient and rapid way of analyzing multiple targets simultaneously from as little as 10ng of total RNA isolated from formalin-fixed, paraffin-embedded (FFPE) samples.
In this webinar, our speakers will show how Thermo Fisher Scientific’s Oncomine Immune Response Research Assay enables the interrogation of gene targets that are critical for research into immune response.
Topics to be covered:
Key learning objectives for attendees:
Who should attend:
For Research Use Only. Not for use in diagnostic procedures.
Medical Laboratory Technician5%
Clinical Laboratory Scientist2%
Life Science Company3%
Medical Device Company1%